GoldenGolden
Antidote.me

Antidote.me

Antidote.me closes the gap between clinical trials and patients

A New York City, New York, London, U.K., and Carmel, IN based company developing artificial intelligence to increase efficiency between medical treatment and research by matching clinical trials with patients. Antidote.me was originally launched as TrialReach in 2010 and rebranded to Antidote.me in 2016.

The company uses a partner network made up of 300+ patient advocacy groups, health portals, bloggers, lab and data partners, and social media to refer patients to clinical trials. Its areas of therapeutic focus includes:

  • Allergy and Immunology
  • Arthritis
  • Autoimmune
  • Cardiology
  • CNS
  • Dermatology
  • Gastroenterology
  • IBS
  • Liver disease
  • Metabolic
  • Ophthalmology
  • Rare disease
  • Renal
  • Respiratory
Antidote Match

Antidote Match is the core of Antidote.me' platform. The software works to match trials to patients. The software uses industry standard and custom-designed ontologies with their proprietary algorithms to explore patients eligibility for trials. Through the software, patient's can find studies based on the same indicators, and they can find information on the studies and scientists and treatments involved in the clinical trials.

During the COVID-19 pandemic, Antidote.me offered their Antidote Match platform for free in order to try and speed up the process of connecting possible patients to COVID-19 trials.

Timeline

April 14, 2020
Antidote Technologies added COVID-19 trials to their clinical trial search platform.
January 4, 2018
Inspire and Antidote announced a strategic collaboration today to provide an end-to-end patient recruitment model to pharmaceutical companies and CROs.
February 5, 2015
TrialReach Raises $13.5M Series B To Match Patients To Clinical Trials
May 8, 2013
TrialReach, a startup focused on making clinical trials more accessible, has announced a £2 million ( $3.1 million) funding round in order to further develop its product.
October 28, 2011
Antidote.me raises a $1,200,000 venture round from Amadeus Capital Partners.
2010
Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016.

Funding rounds

Funding round
Description
Funding type
Funding round amount (USD)
Funding round date
Investment
Antidote.me Venture Funding Round, September 2017

Antidote.me raises $11M in Venture Round, September 2017

11,000,000

Antidote.me raises $13.5M in Series B Funding round - February, 2015

13,500,000

Antidote.me raised $1,200,000 in Venture Round - October, 2011

1,200,000
October 28, 2011

Antidote.me raised an undisclosed amount on in Venture Round, April 2016

5 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dean Sellis

VP of Engineering

Grace McElroy

VP of Marketing & Partnerships

Kathleen Freeman

Vice President of Business Development

Keith Lovell

Chief Financial Officer

Kulvinder Maingi

Cheif Technology Officer

Thomas Krohn

Cheif Development Officer

Further reading

Title
Author
Link
Type
Date

6 Ways Patients Can Find Clinical Trials Worldwide

Web

November 9, 2017

Antidote Technologies Inc - Company Profile and News

Web

Antidote Technologies raises $11M to speed development of trial matching platform

Jeff Lagasse

Web

September 7, 2017

Antidote Technologies Unveils Smart COVID-19 Clinical Trial Search to Speed Up Treatment and Vaccine Research Worldwide

Business Wire

Web

April 14, 2020

Antidote Technologies' Laurent Schockmel Recognized as a Top 40 Healthcare Transformer

markets.businessinsider.com

Web

March 21, 2019

New LRA and Antidote Technologies Study Finds Clinical Trial Participation by Minorities Lagging - Lupus Research

Lupus Research Alliance

Web

February 20, 2020

TrialReach Raises $13.5M Series B To Match Patients To Clinical Trials

Steve O'Hear

Web

February 5, 2015

Documentaries, videos and podcasts

Title
Date
Link

Clinical trial resources for patients

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.